Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT00659568 Completed - Breast Cancer Clinical Trials

Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma

Start date: March 2008
Phase: Phase 1
Study type: Interventional

RATIONALE: Metformin and temsirolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of metformin when given together with temsirolimus in treating patients with metastatic or unresectable solid tumor or lymphoma.

NCT ID: NCT00659425 Completed - Clinical trials for Acute Lymphoblastic Leukemia

CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

Start date: September 2008
Phase: Phase 1
Study type: Interventional

A dose-escalation study to estimate maximum cummulative dose (MTCD) of CAT-8015 that can be safely administered to a participant.

NCT ID: NCT00658970 Completed - Lymphoma Clinical Trials

Evaluation of KX2-391 in Patients With Advanced Malignancies

Start date: November 2007
Phase: Phase 1
Study type: Interventional

The purpose of this Phase 1 study is to determine the safety and tolerability of KX2-391 in cancer patients.

NCT ID: NCT00656812 Completed - Clinical trials for Lymphoma of Mucosa-Associated Lymphoid Tissue

Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma

Start date: May 2008
Phase: Phase 2
Study type: Interventional

The purpose of this trial is to evaluate whether a Rituximab plus 2 CdA combination therapy is effective and safe in the treatment of patients with advanced or relapsed lymphoma of the mucosa associated lymphoid tissue (MALT).

NCT ID: NCT00655837 Completed - Clinical trials for Lymphoma, Non-Hodgkin

Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL

Start date: April 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine safety and tolerability of combination therapy of SGN-40 with gemcitabine and rituximab for the treatment of lymphoma. This study is also intended to estimate how well your disease responds to this treatment.

NCT ID: NCT00654732 Completed - Clinical trials for Classic Hodgkin Lymphoma

Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma

Start date: March 19, 2008
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well combination chemotherapy with or without rituximab works in treating participants with stage III-IV classic Hodgkin lymphoma. Monoclonal antibodies, such as rituximab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as doxorubicin hydrochloride, bleomycin, vinblastine, and dacarbazine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving rituximab with combination chemotherapy may work better in treating participants with classic Hodgkin lymphoma.

NCT ID: NCT00651755 Completed - Lymphoma Clinical Trials

Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients

Start date: March 2008
Phase: N/A
Study type: Interventional

The goal of this clinical research study is to learn the effect of combining aprepitant with CHOP or R-CHOP in patients with Non-Hodgkin's Lymphoma (NHL) that is either newly diagnosed or has come back. Researchers also want to see if aprepitant can help to prevent nausea and/or vomiting that may be caused by chemotherapy treatment with CHOP or R-CHOP, in these patients. CHOP consists of four drugs - Cyclophosphamide (also called Cytoxan/Neosar), Doxorubicin (or Adriamycin), Vincristine (Oncovin) and Prednisolone while R-CHOP includes Rituximab and CHOP.

NCT ID: NCT00647764 Completed - Lymphoma Clinical Trials

Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas

Start date: March 2008
Phase: Phase 1
Study type: Interventional

Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.

NCT ID: NCT00646854 Completed - Clinical trials for Lymphoma, T-Cell, Peripheral

Alemtuzumab and CHOP in T-cell Lymphoma

ACT-1
Start date: June 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine efficacy and safety of the monoclonal antibody MabCampath® (alemtuzumab) combined with chemotherapy in the treatment of T-cell lymphoma.

NCT ID: NCT00646139 Completed - Lymphoma Clinical Trials

KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment

Start date: October 2007
Phase: Phase 1
Study type: Interventional

RATIONALE: KX2-391 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of KX2-391 in treating patients with advanced solid tumors or lymphoma that did not respond to treatment.